Register Login
Register to leave comments
  • News bot March 24, 2026, 1:19 p.m.

    📋 BIOAGE LABS, INC. (BIOA) - Financial Results

    Filing Date: 2026-03-24

    Accepted: 2026-03-24 09:10:30

    Event Type: Financial Results

    Event Details:

    BIOAGE LABS, INC. (BIOA) Reports the reporting period Financial Results BIOAGE LABS, INC. (BIOA) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 4674
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 188888
      • In December 2025, BioAge announced positive interim data from the ongoing Phase 1 single ascending dose (SAD) / multiple ascending dose (MAD) trial of BGE
      • penetrant NLRP3 inhibitor. BGE
      • 102 was well tolerated across all doses, with dose
        • anticipated in mid-2027
        • targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. Forward-looking statements This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995
        • targeting the biology of human aging, today provided financial results for the full year ended December 31, 2025

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Operating Expenses Loss From Operations 92.78K 78.19K $14.59K +18.65%
    Other Income Expense Net Interest Expense 697.00 2.37K $-1.67K -70.55%
    Other Income Expense Net Total Other Income Expense 12.18K 7.08K $5.09K +71.84%
    Other Income Expense Net Net Loss 80.61K 71.11K $9.50K +13.35%
    Comprehensive Loss Net Loss 80.61K 71.11K $9.50K +13.35%
    Current Assets Prepaid Expenses Other Current Assets 4.93K 2.75K $2.17K +78.87%
    Current Assets Property Equipment Net 963.00 591.00 $372.00 +62.94%
    Current Assets Operating Lease Right Of Use Assets 2.79K 200.00 $2.58K +1292.50%
    Current Assets Other Assets 216.00 240.00 $-24.00 -10.00%
    Current Liabilities Accounts Payable 2.67K 2.00K $678.00 +33.97%
    Loss from Operations 92.78K 78.19K $14.59K +18.65%
    Interest Expense 697.00 2.37K $-1.67K -70.55%
    Total Other Income/(Expense) 12.18K 7.08K $5.09K +71.84%
    Net Loss 80.61K 71.11K $9.50K +13.35%
    Prepaid Expenses and Other Current Assets 4.93K 2.75K $2.17K +78.87%
    Property and Equipment, Net 963.00 591.00 $372.00 +62.94%
    Other Assets 216.00 240.00 $-24.00 -10.00%
    Accounts Payable 2.67K 2.00K $678.00 +33.97%
    Operating Lease Liabilities 582.00 202.00 $380.00 +188.12%
    Revenue 5.75K 7.83K $-2.07K -26.48%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BIOAGE LABS, INC.
    • Ticker Symbol: BIOA

Search

News categories